Literature DB >> 23084565

Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study.

Nikolaos P Polyzos1, Michel Devos, Peter Humaidan, Dominic Stoop, Carolina Ortega-Hrepich, Paul Devroey, Herman Tournaye.   

Abstract

OBJECTIVE: To identify whether women with poor ovarian response may benefit from treatment with corifollitropin alfa in a GnRH antagonist protocol.
DESIGN: Retrospective pilot study.
SETTING: University-based tertiary care center. PATIENT(S): Poor ovarian responders fulfilling the Bologna criteria developed by European Society for Human Reproduction and Embryology Consensus Group. INTERVENTION(S): Corifollitropin alfa (150 μg) followed by 300 IU rFSH in a GnRH antagonist protocol. MAIN OUTCOME MEASURE(S): Endocrinologic profile and ongoing pregnancy rates. RESULT(S): Among 43 women treated with corifollitropin alfa, mean E(2) levels showed an increasing pattern during the follicular phase, reaching 825 ng/L on the day of hCG administration, whereas FSH values showed a marked increase during the first 5 days, reaching a mean value of 35 IU/L and remaining above 20 IU/L during the late follicular phase. Cycle cancellation rate was 32.6% and embryo transfer rate 53.3%. Five patients (11.7%) had a positive hCG test and three (7%) had an ongoing pregnancy. Ongoing pregnancy rates were 11.1% per oocyte retrieval and 13% per embryo transfer. Ongoing pregnancy rates per patient did not significantly differ compared with a cohort of patients treated during 2011 with the standard protocol for poor responders in our center (short agonist-hMG) (7% vs. 6.3%). CONCLUSION(S): Treatment of poor ovarian responders, as described by the Bologna criteria, with corifollitropin alfa in a GnRH antagonist protocol results in low pregnancy rates, similarly to conventional stimulation with a short agonist protocol.
Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23084565     DOI: 10.1016/j.fertnstert.2012.09.043

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  11 in total

1.  Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System.

Authors:  Kate Devine; Sunni L Mumford; Mae Wu; Alan H DeCherney; Micah J Hill; Anthony Propst
Journal:  Fertil Steril       Date:  2015-06-11       Impact factor: 7.329

2.  Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-control study.

Authors:  Alberto Revelli; Giulia Pittatore; Simona Casano; Stefano Canosa; Francesca Evangelista; Chiara Benedetto
Journal:  J Assist Reprod Genet       Date:  2015-01-15       Impact factor: 3.412

3.  Corifollitropin α followed by menotropin for poor ovarian responders' trial (COMPORT): a protocol of a multicentre randomised trial.

Authors:  Nikolaos P Polyzos; Michel Camus; Joaquin Llacer; Konstantinos Pantos; Herman Tournaye
Journal:  BMJ Open       Date:  2013-06-20       Impact factor: 2.692

4.  Efficacy of corifollitropin alfa followed by recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist protocol for Korean women undergoing assisted reproduction.

Authors:  Hyo Young Park; Min Young Lee; Hyo Young Jeong; Yong Sook Rho; Sang Jin Song; Bum-Chae Choi
Journal:  Clin Exp Reprod Med       Date:  2015-06-30

Review 5.  Management of poor responders in IVF: is there anything new?

Authors:  Filippo Ubaldi; Alberto Vaiarelli; Rosario D'Anna; Laura Rienzi
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

Review 6.  Fertility with early reduction of ovarian reserve: the last straw that breaks the Camel's back.

Authors:  Sabahat Rasool; Duru Shah
Journal:  Fertil Res Pract       Date:  2017-10-11

7.  Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients.

Authors:  Helmy Selman; Leonardo Rinaldi
Journal:  Int J Womens Health       Date:  2016-10-17

8.  Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol.

Authors:  Lister L Salgueiro; Juliana R Rolim; Bernardo R L Moura; Suelen P P Machado; Carolina Haddad
Journal:  JBRA Assist Reprod       Date:  2016-08-01

9.  Corifollitropin alfa for poor responders patients, a prospective randomized study.

Authors:  F M Fusi; L Zanga; M Arnoldi; S Melis; M Cappato; I Candeloro; A Di Pasqua
Journal:  Reprod Biol Endocrinol       Date:  2020-07-09       Impact factor: 5.211

10.  Prediction of in vitro fertilization outcome at different antral follicle count thresholds combined with female age, female cause of infertility, and ovarian response in a prospective cohort of 8269 women.

Authors:  ShuJie Liao; Jianwu Xiong; Haiting Tu; Cheng Hu; Wulin Pan; Yudi Geng; Wei Pan; Tingjuan Lu; Lei Jin
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.